# Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)

> **NCT01070745** · PHASE2 · WITHDRAWN · sponsor: **Shaare Zedek Medical Center**

## Conditions studied

- Patent Ductus Arteriosus

## Interventions

- **DRUG:** Indomethacin
- **DRUG:** Ibuprofen

## Key facts

- **NCT ID:** NCT01070745
- **Lead sponsor:** Shaare Zedek Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2012-06
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Changes in approach to PDA therapy
- **Last updated:** 2012-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01070745

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01070745, "Second Course of Therapy for Resistant Patent Ductus Arteriosus (PDA)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01070745. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*